Research Papers:
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1862 views | HTML 2873 views | ?
Abstract
Markus Eckstein1,*, Ralph M. Wirtz2,3,*, Carolin Pfannstil1,*, Sven Wach4,*, Robert Stoehr1,*, Johannes Breyer6,*, Franziska Erlmeier7,*, Cagatay Günes8,*, Katja Nitschke5,*, Wilko Weichert7,*, Wolfgang Otto6,*, Bastian Keck4,*, Sebastian Eidt3,*, Maximilian Burger6,*, Helge Taubert4,*, Bernd Wullich4,*, Christian Bolenz8,*, Arndt Hartmann1,* and Philipp Erben5,*
1Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
2STRATIFYER Molecular Pathology GmbH, Cologne, Germany
3Institute of Pathology at The St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
4Department of Urology, University of Erlangen-Nuremberg, Erlangen, Germany
5Department of Urology Mannheim, University of Heidelberg, Mannheim, Germany
6Department of Urology, University of Regensburg, Regensburg, Germany
7Institute of Pathology, Technical University Munich, Munich, Germany
8Department of Urology, University of Ulm, Ulm, Germany
*On behalf of the BRIDGE-Consortium Germany
Correspondence to:
Markus Eckstein, email: [email protected]
Keywords: bladder cancer; PD-L1; checkpoint inhibitors; molecular therapy stratification; immunohistochemistry
Received: October 26, 2017 Accepted: February 10, 2018 Epub: February 19, 2018 Published: March 13, 2018
ABSTRACT
Background: Immunohistochemical PD-L1 assessment is currently used to identify responders towards checkpoint inhibitors although it is limited by inter-observer effects. Here, we conducted a multi-center round robin test to prove the possibility of assessing the PD-L1 status by gene expression to avoid inter-observer effects.
Patients and methods: Gene expression of PD-L1 was analyzed in a total of 294 samples (14 cases non-muscle invasive and muscle-invasive bladder cancer; MIBC) in seven centers by a RT-qPCR kit and compared with immunohistochemical scoring of three pathologists (DAKO, 22c3). Both assays were compared towards prognosis prediction in a cohort of 88 patients with MIBC.
Results: PD-L1 gene expression revealed very high inter center correlation (centrally extracted RNA: r = 0.68–0.98, p ≤ 0.0076; locally extracted RNA: r = 0.81–0.98, p ≤ 0.0014). IHC Inter-observer concordance was moderate to substantial for immune cells (IC), fair for combined IC/ tumor cell (TC) (IC: κ = 0.50–0.61; IC + TC: κ = 0.50), and fair for TC scoring (κ = 0.26–0.35). Gene expression assessment resulted in more positive cases (9/14 cases positive vs. 6/14 cases [IHC]) which could be validated in the independent cohort. Positive mRNA status was associated with significantly better overall and disease-specific survival (5-year OS: 50% vs. 26%, p = 0.0042, HR = 0.48; 5 year DSS: 65% vs. 40%, p = 0.012, HR = 0.49). The 1% IHC IC cut-off also revealed significant better OS (5 year OS: 58% vs. 31%, p = 0.036, HR = 0.62).
Conclusion: Gene expression showed very high inter-center agreement. Gene expression assessment also resulted in more positive cases and revealed better prognosis prediction. PD-L1 mRNA expression seems to be a reproducible and robust tool for PD-L1 assessment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24531